DISC MEDICINE INC (IRON)
US2546041011 - Common Stock
DISC MEDICINE INC
NASDAQ:IRON (11/22/2024, 8:00:02 PM)
After market: 64.96 0 (0%)64.96
+1.45 (+2.29%)
Company Profile
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Company Info
DISC MEDICINE INC
321 Arsenal Street, Suite 101
Watertown MASSACHUSETTS
P: 16176749274
Employees: 74
Website: https://www.discmedicine.com/
IRON News
11 days ago - Disc Medicine IncDisc Medicine to Participate in Upcoming Investor Conferences11 days ago - Disc Medicine IncDisc Medicine to Participate in Upcoming Investor ConferencesWATERTOWN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the...
12 days ago - Disc Medicine IncDisc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update12 days ago - Disc Medicine IncDisc Medicine Reports Third Quarter 2024 Financial Results and Provides Business UpdateCompleted a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study...
16 days ago - Disc Medicine IncDisc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.16 days ago - Disc Medicine IncDisc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.WATERTOWN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it has obtained a $200 million non-dilutive term loan facility from Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. This financing provides funding options to support anticipated key catalysts, including the expected initiation of a confirmatory study of bitopertin in erythropoietic protoporphyria (EPP), a Phase 2 study of DISC-0974 in anemia of myelofibrosis (MF) and a multiple dose study in anemia of non-dialysis dependent chronic kidney disease (NDD-CKD), and a Phase 2 study of DISC-3405 in polycythemia vera (PV).
IRON Twits
Here you can normally see the latest stock twits on IRON, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
